Tumor microenvironment immune pathways (TME immune pathways)

The tumor microenvironment (TME) immune pathways represent the intricate network of signaling and cellular interactions between cancer cells and the surrounding immune landscape, including T cells, natural killer cells, and myeloid-derived suppressor cells (Binnewies et al., 2018, Nature Medicine). These pathways are frequently co-opted by tumors to create an immunosuppressive milieu, facilitating immune evasion and disease progression through the activation of inhibitory checkpoints like PD-1/PD-L1 and CTLA-4 (Pitt et al., 2016, Annals of Oncology). Therapeutic intervention focuses on blocking these inhibitory signals or enhancing stimulatory pathways to restore the host's anti-tumor immune response (Chen & Mellman, 2013, Immunity). Beyond checkpoints, the TME involves metabolic reprogramming and cytokine-mediated communication, such as TGF-beta and IL-10 signaling, which further dampen immune efficacy (Gajewski et al., 2013, Nature Immunology). Understanding the spatial and functional heterogeneity of these pathways is essential for refining immunotherapy and identifying predictive biomarkers for clinical success. Because this term refers to a broad biological concept rather than a single molecular entity, it is classified as a pathway collection rather than a specific therapeutic target.

Other names

Tumor immune microenvironmentTIMETME signaling pathwaysCancer-immune crosstalkImmune evasion pathways

Modulation of immune checkpoints, cytokine signaling, and metabolic pathways to restore anti-tumor immunity.